Parkon® in the treatment of multiple sclerosis. A pilot study
<p>Multiple Sclerosis (MS) is one of the most common chronic demyelinating diseases of the central nervous system. The disease affects and relatively quickly leads to disability in mainly people 15-40 years of age. The development of MS can occur progressively or with exacerbations and remissi...
Gorde:
Egile Nagusiak: | Goldstein NI (Egilea), Golubev VL (Egilea), Goldstein RN (Egilea) |
---|---|
Formatua: | Liburua |
Argitaratua: |
Open Journal of Parkinson's Disease and Treatment - Peertechz Publications,
2020-08-07.
|
Gaiak: | |
Sarrera elektronikoa: | Connect to this object online. |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Antzeko izenburuak
-
Parkon as a treatment of the Parkinson's disease
nork: Golubev VL, et al.
Argitaratua: (2019) -
The results of a clinical and neurophysiological study of the effectiveness of Parkon spray in the treatment of Parkinson's Disease (PD)
nork: Gekht BM, et al.
Argitaratua: (2022) -
Multi-center clinical study of Parkon® efficiency
nork: Fjodorova NE, et al.
Argitaratua: (2021) -
How does medicine Parkon® affect the MPTP-induced oxidation stress and MAO systems of the rats brain
nork: N Goldstein, et al.
Argitaratua: (2021) -
Rehabilitation treatment in multiple sclerosis
nork: Katarzyna Ciechanowska, et al.
Argitaratua: (2018)